Also Known As: Cefdinir, Omnicef

Cefdinir (marketed by Hikma Pharmaceuticals under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December 1997.

As of 2008, cefdinir was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone.

Therapeutic uses of cefdinir include otitis media, soft tissue infections, and respiratory tract infections, including sinusitis, strep throat, community-acquired pneumonia and acute exacerbations of bronchitis.

Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Complete a survey on Cefdinir to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.